News

An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.

The approval was based on a comprehensive assortment of studies which showed adalimumab-aaty was comparable to the reference product, adalimumab.

In this episode, Veeral Sheth, MD, sits down with Jay Duker, MD for a discussion on his storied career, fostering relationships with industry, and the current technology being worked on at Eyepoint Pharmaceuticals for retinal disorders.

New data indicates the usefulness of spironolactone as an alternative to oral antibiotics for women in the UK with acne vulgaris, given increasing resistance to antibiotics due to widespread use.

An analysis of data from the NODE-303 trial provides insight into the effects of etripamil nasal spray in people with atrial fibrillation with rapid ventricular rates.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

Presented at the European Stroke Conference, results of the ELAN trial offer evidence in support of early initiation, as opposed to later initiation, strategies for anticoagulation following acute ischemic stroke in patients with atrial fibrillation.

New data from a systematic review of randomized control trials indicated that moderate-to-severe psoriasis patients benefited from deucravacitinib as a first line treatment.

The prevalence rate was the highest in methadone clinics followed by correctional institutions, HIV clinics, and the surveillance program.

Unlike other screenings, lung cancer screening is new and patients need to know what happens next, according to Dr. Panagis Galiatsatos.

Pregnancy and delivery are risky times for both mother and child for a number of reasons, but do you know by how much rheumatoid arthritis can increase those risks? Test your knowledge with this quiz.

Buprenorphine is available either in a weekly injection formulation and a monthly formulation for patients already being treated with buprenorphine.

A new analysis found differences in the gut bacteria seen in adults with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity may begin in early childhood.

Dr. Rutland emphasizes the importance of understanding cellular communication and its potential to manipulate disease processes for patient benefit, including the observed link between ILD, inflammation, scarring, and pulmonary hypertension.

In this interview, Marinkovich discussed the implications of the FDA’s landmark approval of B-VEC topical gene therapy for patients with the “butterfly disease.”

The interrupted time-series resulted in an increase in C. difficile infection incidences during the pre-pandemic period from 0.00 to 3.36 infections per 10,000 bed days during the COVID-19 pandemic.

An analysis of cost-effectiveness using data from SOLOIST-WHF provides insight into the varying cost-effectiveness of the agent as a treatment for worsening heart failure.

The approval was based on data from a pharmacodynamic study which showed nalmefene provided a fast onset of reversal of respiratory depression from the synthetic opioid remifentanil.

During this interview segment, Stucky continued on his team's findings on a newspaper article’s association with increased prescribing rates of oral minoxidil, explaining the study’s limitations and implications.

Promising results from the ATS Conference suggest that AD109, an oral treatment for obstructive sleep apnea, demonstrated significant reduction of AHI and potential mitigation of daytime fatigue.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

More data is needed to determine whether low-dose levodopa use reduces conversion to neovascular AMD.

Modified production of abicipar was linked to a moderately lower incidence and severity of IOI in nAMD eyes compared with Phase 3 results, but further reductions in IOI are required to match the incidence rates of other anti-VEGF therapies.

In this interview, Stucky discussed his team’s research into an uptick in oral minoxidil prescribing rates for hair loss that had immediately followed the publication of a New York Times article.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

Muthiah Vaduganathan, MD, MPH, offers perspective on data from the PARAGLIDE-HF trial as well as a pooled analysis of data from the PARAGLIDE-HF and PARAGON-HF trials.

There is no additional risk of developing new cancers for patients treated with IBD medications.